17 results about "Genus Shigella" patented technology

The invention relates to the field of biological medicine, in particular to a construction method of a novel marine source 4-hydroxybenzoxazole-2 (3H)-thioketone carrier based on a beta-cyclodextrin metal organic framework and application of the novel marine source 4-hydroxybenzoxazole-2 (3H)-thioketone carrier to antibacterial activity enhancement. According to the invention, the effect of 4-hydroxybenzoxazol-2 (3H)-thioketone (HBOT) on resisting escherichia coli and shigella flexneri is found. The result shows that the antibacterial diameter of the HBOT on shigella flexneri is 15.78 + / -0.67 mm, and the antibacterial diameter of the HBOT on escherichia coli is 10.81 + / -0.50 mm; the MIC of the free HBOT to shigella flexneri is 128 [mu] g / mL, and the MIC of the beta-CD-MOF loaded with the free HBOT is 64 [mu] g / mL, so that the beta-CD-MOF loaded with the free HBOT has the capability of enhancing the antibacterial performance.

The present application relates to the field of pharmaceutical chemistry, and specifically discloses a emodin mannich base, a preparation method and application thereof. The emodin mannich base has a structure as shown in formula I, the structure is simple, has strong in-vitro antimicrobial activity, especially high inhibitory activity to staphylococcus aureus, bacillus subtilis, micrococcus luteus, escherichia coli, proteus vulgaris, pseudomonas aeruginosa, shigella dysenteriae, salmonella typhimurium and other bacteria, and candida utilis, candida albicans, saccharomyces cerevisiae, monascus and other fungi, and can be used for preparing antibacterial and / or antifungal drugs.

Provided herein are vaccine compositions for preventing and combating infection by Shigella. In particular, the present disclosure provides a composition comprising a Shigella virulence factor VirG (or IcsA) protein or a fragment thereof comprising about 100-400 amino acids of the VirG protein having an amino acid sequence that is at least 90% identical to the sequence set forth in SEQ ID NO: 2.

The invention relates to shigella flexneri as well as related serotype and application of a preparation of the shigella flexneri in preparation of anti-tumor immune activation and treatment medicines. The shigella flexneri and the preparation thereof disclosed by the invention can improve a tumor immune microenvironment by activating anti-tumor immune response of an organism so as to inhibit tumor growth, and are suitable for prevention and / or treatment of various tumors; the strain and the preparation thereof can be independently used and can also be combined with existing tumor therapies such as chemotherapy, radiotherapy and immunotherapy to synergistically enhance the anti-tumor curative effect; the invention provides a new microbial resource and strategy for tumor immunotherapy, and has an important clinical application prospect.

The invention belongs to the technical field of PCR detection, and particularly relates to a composition for detecting pathogenic bacteria, a kit, application and a detection method. The pathogenic bacteria are any one or more of enterococcus faecalis, escherichia coli, klebsiella pneumoniae, enterobacter cloacae, enterococcus faecium and shigella flexneri pathogens, and the composition comprises any one or more of a component A, a component B, a component C, a component D, a component E and a component F; the composition comprises forward and reverse primers and probes aiming at enterococcus faecalis, escherichia coli, klebsiella pneumoniae, enterobacter cloacae, enterococcus faecium and shigella flexneri. The composition provided by the invention can simultaneously detect and distinguish enterococcus faecalis, escherichia coli, klebsiella pneumoniae, enterobacter cloacae, enterococcus faecium and shigella flexneri, has high sensitivity, specificity and precision, is helpful to take treatment measures in time and customize personalized treatment schemes, reduces unnecessary use of antibiotics, and has a good application prospect. The generation of drug resistance is reduced.

The present invention provides an antigenic nitrated recombinant polypeptide derived from invasion plasmid antigen D (IpaD) of Shigella flexneri. Also provided is a vaccine composition comprising the antigenic nitrated recombinant polypeptide and preparation thereof. Further provided is a method for inducing an immune response in a subject, comprising administering the vaccine composition to the subject.

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The invention discloses a group of antibacterial polypeptides aiming at gram-negative bacteria, and belongs to the technical field of biological medicines. According to the invention, a group of antibacterial peptides is obtained through screening, and the antibacterial peptides have good broad-spectrum antibacterial performance on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia. Wherein the hemolytic activity and toxicity of the antibacterial peptides 11A-1, 11A-4 and 11A-5 are lower than therapeutic concentration threshold values, and the antibacterial peptides 11A-1, 11A-4 and 11A-5 can be used for preparing drugs or medical products for treating multi-drug-resistant bacterial infection.

The invention discloses application of pH-ROS dual-response fullerol gel in improvement of intestinal microbiota and colitis, and belongs to the technical field of biological pharmacy. The invention provides an application of pH-ROS dual-response fullerol gel SA-DA / CMCS-FPBA-coated C60 (OH) 12 in treatment of ulcerative colitis by regulating intestinal microbiota. The fullerol gels can treat colitis by promoting a substantial increase in beneficial bacteria of the genus Bifidobacterium, thereby reducing other harmful bacteria and maintaining the levels of probiotics of the genus Shigella, Enterococcus and Fecalis. After being applied, the compound has a potential effect of maintaining the steady state of microorganisms for patients suffering from ulcerative colitis, has the characteristics of low toxicity, high efficiency and the like, and has a good drug development prospect.

The invention relates to a conjugate composed of an antigenic peptide presenting an epitope of the Shigella flexneri 3a OmpC protein of SEQ ID NO: 1, conjugated via the C- terminal residue of the peptide to a human serum albumin (MSA) carrier protein molecule, a vaccine composition containing said conjugate, and its use for preventing bacterial infections caused by Shigella bacteria.

The application discloses a screening method, platform and application of human intestinal alpha defensin 5 (HD5) receptor P2Y11, and belongs to the field of biological medicines. The method fuses multiple omics and experimental strategies, effectively solves the problems of complex receptor proteins and difficult independent identification of interactions, significantly improves the accuracy and reliability of defensin receptor identification, and provides a method system with strong universality and wide applicability for receptor research. The method successfully identifies the first cell receptor P2Y11 of HD5. The discovery of the P2Y11 receptor not only opens up a new perspective for in-depth understanding of the biological function and mechanism of HD5, but also provides a new potential target for the treatment of related diseases. In particular, for infectious diseases such as bacterial dysentery caused by Shigella and the like in which HD5 is involved, the P2Y11 receptor as a drug target provides a possibility for developing a new treatment scheme, and is expected to bring more effective treatment options for patients, and significantly improve the treatment effect and the quality of life.

The application discloses an intestinal flora regulator containing unsaturated oligogalacturonic acid and application thereof, and an effective component of the intestinal flora regulator containing unsaturated oligogalacturonic acid comprises lemon unsaturated oligogalacturonic acid with a molecular weight of 80-85 kDa and an unsaturation degree of 7-10. The application finds that the intestinal flora regulator containing unsaturated oligogalacturonic acid has a regulating effect on intestinal flora by simulating an in-vivo environment in vitro and collecting intestinal microorganisms in human feces, including regulating the abundance, structure and diversity of intestinal flora, promoting the proliferation of beneficial bacteria such as bifidobacterium and lactobacillus, and inhibiting the proliferation of escherichia shigella and bacteroides, and can provide help for the development of intestinal disease treatment drugs.

The invention belongs to the field of gene detection, and particularly relates to a characteristic gene combination for predicting antibiotic susceptibility phenotype of shigella sonnei, a kit and application of the characteristic gene combination. The drug sensitive phenotype of shigella sonnei to antibiotics is judged by detecting specific genes or mutation, the method has the advantages of high accuracy, high sensitivity and high specificity, and accurate diagnosis and treatment of infection are facilitated.

The invention provides a berberine derivative as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the derivative, an acyl acetophenone substituent group is introduced to the 9 site of berberine, and a series of 9-site substituted berberine compounds are specifically designed and synthesized. In-vitro antimicrobial activity detection shows that the compounds have excellent inhibitory activity on gram-positive bacteria (staphylococcus aureus and methicillin-resistant staphylococcus aureus) and gram-negative bacteria (escherichia coli, shigella flexneri, shigella dysenteriae and vibrio parahaemolyticus), can be used for preparing antibacterial drugs, do not have obvious drug resistance, and can be used for preparing antibacterial drugs. And a more efficient and safer candidate drug can be provided for the treatment of clinical diarrhea related diseases.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.

The present application relates to the field of biological medicine, in particular to a kind of marine source 4-hydroxybenzoxazole-2 (3H) -thione novel carrier construction method based on β-cyclodextrin metal organic framework and its application for enhancing antibacterial activity.The present application finds that 4-hydroxybenzoxazole-2 (3H) -thione (HBOT) can inhibit the growth of escherichia coli and shigella flexneri.The results show that the inhibition diameter of HBOT on shigella flexneri is 15.78±0.67mm, and the inhibition diameter of HBOT on escherichia coli is 10.81±0.50mm;The MIC of free HBOT on shigella flexneri is 128 μg / mL, and the MIC of β-CD-MOF loaded with free HBOT is 64 μg / mL, so β-CD-MOF loaded with free HBOT has the ability to enhance antibacterial performance.

The present invention discloses a polypeptide drug for use against Gram-negative bacteria and its application, belonging to the field of biomedicine. The antimicrobial peptide screened and obtained by the present invention has broad-spectrum antibacterial properties, with MICs of 16 μg / mL, 2 μg / mL, 16 μg / mL, 4 μg / mL, 2 μg / mL, and 4 μg / mL against Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa, Klebsiella pneumoniae, Shigella sonnei, and Stenotrophomonas maltophilia, respectively. Its hemolytic and toxic properties are below the therapeutic concentration threshold, and it can be used to prepare drugs or medical products for treating multidrug-resistant bacterial infections.